bpc 157 human clinical trials status 2025 Eleven that will shape medicine in BPC-157 as a Healing Peptide

Strong evidence, from decades of treating individuals with inborn errors of B 12 metabolism, supports the safety of parenteral, lifelong, even high dose hydroxocobalamin, sometimes even at very high doses.6768 Long term epidemiological studies also indicate that treatment with pharmacological B 12 doses and the corresponding increase in serum B 12 do not increase mortality.69 Data on the safety of cyanocobalamin, when administered with high frequency (ie, one to two times a week) for a longer period of time, are lacking

has less power cost, larger flow, and great anticorrosion ability

Therefore, we performed pharmacokinetic studies of BPC157 in beagle dogs following single IV administration at a dose of 6 g/kg, single IM administration at doses of 6, 30, or 150 g/kg, and repeated IM administration at a dose of 30 g/kg for seven consecutive days

doi:10.1016/j.anl.2004.03.005